BSE Live
Oct 10, 16:01Prev. Close
881.70
Open Price
881.75
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Oct 10, 15:59Prev. Close
881.50
Open Price
881.50
Bid Price (Qty.)
904.75 (5)
Offer Price (Qty.)
0.00 (0)
Profit & Loss account of Cohance Lifesciences (in Rs. Cr.) | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 | |
12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
INCOME | ||||||
Revenue From Operations [Gross] | 1,172.28 | 1,035.85 | 1,331.11 | 1,307.01 | 995.46 | |
Less: Excise/Sevice Tax/Other Levies | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Revenue From Operations [Net] | 1,172.28 | 1,035.85 | 1,331.11 | 1,307.01 | 995.46 | |
Total Operating Revenues | 1,197.58 | 1,051.35 | 1,340.33 | 1,320.22 | 1,009.72 | |
Other Income | 58.56 | 61.91 | 46.36 | 92.38 | 14.24 | |
Total Revenue | 1,256.14 | 1,113.26 | 1,386.69 | 1,412.60 | 1,023.96 | |
EXPENSES | ||||||
Cost Of Materials Consumed | 222.66 | 265.88 | 430.08 | 459.46 | 310.32 | |
Purchase Of Stock-In Trade | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Operating And Direct Expenses | 0.00 | 133.48 | 176.29 | 173.19 | 122.73 | |
Changes In Inventories Of FGWIP And Stock In Trade | 82.63 | 49.16 | -20.94 | -60.35 | -8.37 | |
Employee Benefit Expenses | 249.56 | 135.92 | 110.51 | 100.48 | 87.29 | |
Finance Costs | 12.35 | 7.45 | 5.44 | 6.23 | 9.14 | |
Depreciation And Amortisation Expenses | 77.49 | 54.60 | 47.73 | 39.10 | 31.64 | |
Other Expenses | 267.53 | 61.11 | 77.86 | 68.02 | 57.27 | |
Total Expenses | 912.22 | 707.59 | 826.96 | 786.12 | 610.02 | |
Profit/Loss Before Exceptional, ExtraOrdinary Items And Tax | 343.92 | 405.67 | 559.73 | 626.48 | 413.94 | |
Exceptional Items | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Profit/Loss Before Tax | 343.92 | 405.67 | 559.73 | 626.48 | 413.94 | |
Tax Expenses-Continued Operations | ||||||
Current Tax | 86.77 | 99.58 | 146.27 | 190.40 | 101.54 | |
Less: MAT Credit Entitlement | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Deferred Tax | -14.19 | 6.59 | 4.34 | 23.38 | 3.62 | |
Other Direct Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Total Tax Expenses | 79.15 | 105.39 | 148.44 | 213.79 | 105.33 | |
Profit/Loss After Tax And Before ExtraOrdinary Items | 264.77 | 300.28 | 411.29 | 412.69 | 308.61 | |
Profit/Loss From Continuing Operations | 264.77 | 300.28 | 411.29 | 412.69 | 308.61 | |
Profit/Loss For The Period | 264.77 | 300.28 | 411.29 | 412.69 | 308.61 | |
Minority Interest | 3.10 | 0.00 | 0.00 | 0.00 | 0.00 | |
Consolidated Profit/Loss After MI And Associates | 267.87 | 300.28 | 411.29 | 453.80 | 362.34 | |
OTHER ADDITIONAL INFORMATION | ||||||
EARNINGS PER SHARE | ||||||
Basic EPS (Rs.) | 11.00 | 12.00 | 16.00 | 18.00 | 14.00 | |
Diluted EPS (Rs.) | 10.00 | 12.00 | 16.00 | 18.00 | 14.00 | |
DIVIDEND AND DIVIDEND PERCENTAGE | ||||||
Equity Share Dividend | 0.00 | 0.00 | 203.65 | 101.83 | 25.46 | |
Tax On Dividend | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
12.06.2025
Cohance Life Standalone March 2025 Net Sales at Rs 330.17 crore, up 35.58% Y-o-Y
04.03.2025
Suven Pharma Consolidated December 2024 Net Sales at Rs 307.15 crore, up 39.73% Y-o-Y
28.11.2024
Suven Pharma Consolidated September 2024 Net Sales at Rs 257.72 crore, up 11.54% Y-o-Y
14.11.2024
Suven Pharma Standalone September 2024 Net Sales at Rs 236.06 crore, up 5.09% Y-o-Y